OPTIMISED COMPOUNDS
The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.
Saved in:
| Main Authors | , , , |
|---|---|
| Format | Patent |
| Language | English |
| Published |
29.07.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections. |
|---|---|
| AbstractList | The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections. |
| Author | Zeng, Weiguang Demaison, Christophe Holmes, Ian Jackson, David |
| Author_xml | – fullname: Zeng, Weiguang – fullname: Jackson, David – fullname: Demaison, Christophe – fullname: Holmes, Ian |
| BookMark | eNrjYmDJy89L5WQQ9g8I8fT1DHZ1UXD29w3wD_VzCeZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfGhwUYGRoZGxkDC3NHQmDhVALD1IRo |
| ContentType | Patent |
| DBID | EVB |
| DatabaseName | esp@cenet |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Sciences |
| ExternalDocumentID | US2021230217A1 |
| GroupedDBID | EVB |
| ID | FETCH-epo_espacenet_US2021230217A13 |
| IEDL.DBID | EVB |
| IngestDate | Fri Jul 19 10:32:31 EDT 2024 |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-epo_espacenet_US2021230217A13 |
| Notes | Application Number: US201816768341 |
| OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210729&DB=EPODOC&CC=US&NR=2021230217A1 |
| ParticipantIDs | epo_espacenet_US2021230217A1 |
| PublicationCentury | 2000 |
| PublicationDate | 20210729 |
| PublicationDateYYYYMMDD | 2021-07-29 |
| PublicationDate_xml | – month: 07 year: 2021 text: 20210729 day: 29 |
| PublicationDecade | 2020 |
| PublicationYear | 2021 |
| RelatedCompanies | Ena Therapeutics Pty Ltd |
| RelatedCompanies_xml | – name: Ena Therapeutics Pty Ltd |
| Score | 3.339797 |
| Snippet | The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or... |
| SourceID | epo |
| SourceType | Open Access Repository |
| SubjectTerms | ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| Title | OPTIMISED COMPOUNDS |
| URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210729&DB=EPODOC&locale=&CC=US&NR=2021230217A1 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNq-LHlIHSt-DM2ro-FHFJyxD6gW1lb6PpEhBkDtfhv-8ldLqnveUDjiRwud_vLncBuJc6GjaXNRlJ5RCn8iQRA6rIk6o8oQTSXJPhHSfepHRep-60A5-bXBhTJ_THFEdEjapR3xtzXy__nVjcvK1cPYgPHPp6joqA2y07Rv6CYNHm4yDMUp4ym7GgzO3kzcwh2kYA_oJcaU8DaV1pP3wf67yU5bZRiY5hP0N5i-YEOnJhwSHb_L1mwUHchryx2Wrf6hSsNCvwrslD3mdpnKVlwvMzuIvCgk0ISp_9bWZW5ttLGZ5DF2m-vIC-q2ptO-eUCul4ovJ96gqnHtYKIcwjHVxCb5ekq93T13Cku9orSf0edJvvtbxBc9qIW3MKv4B4dVY |
| link.rule.ids | 230,309,786,891,25594,76906 |
| linkProvider | European Patent Office |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fS8MwED7GFOebVsXp1IHSt-LM2s4-FHFJS9X1B7aVvZWlS0GQOVzFf99L6HRPews5OJLA3X3fJXcBuBHyNmwuSuNeVKZhzmxh8AGpjFE1s3nFkeaqCu8wsoPcfJ5a0xZ8rGthVJ_QH9UcES2qRHuvlb9e_iexmHpbubrl7zj1-eBnLtMbdoz8BcGizsaul8Qspjqlbp7q0auSIdpGAP6IXGlnJPvzSvD0NpZ1KcvNoOIfwG6C-hb1IbTEQoMOXf-9psFe2Fx547CxvtURaHGSoa9JPdancZjEecTSY7j2vYwGBmov_jZT5OnmUoYn0EaaL06hb1WljJ1zQrgwbT5zHGJxsxyWFUKYOzLoQm-bprPt4ivoBFk4KSZP0cs57EuRzFASpwft-utbXGBorfmlOpFfJK14Qw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=OPTIMISED+COMPOUNDS&rft.inventor=Zeng%2C+Weiguang&rft.inventor=Jackson%2C+David&rft.inventor=Demaison%2C+Christophe&rft.inventor=Holmes%2C+Ian&rft.date=2021-07-29&rft.externalDBID=A1&rft.externalDocID=US2021230217A1 |